Find stats on top websites
Industry Landscape
The medical device industry, particularly in neuromodulation for chronic conditions like OAB and FI, is experiencing robust growth driven by an aging population, rising prevalence of these conditions, and technological advancements. There's a strong focus on less invasive, more patient-friendly solutions. Competition is high, with an emphasis on innovation and market access.
Total Assets Under Management (AUM)
Medical Device Market Size in United States
~Approx. $200 billion USD
(5-6% CAGR)
- Driven by aging population and chronic disease.
- Innovations in minimally invasive procedures.
- Increased adoption of advanced technologies.
Total Addressable Market
500 billion USD
Market Growth Stage
Pace of Market Growth
Emerging Technologies
Closed-Loop Neuromodulation
Closed-loop systems detect physiological signals and automatically adjust stimulation parameters in real-time, optimizing therapy and potentially reducing side effects.
AI-Powered Diagnostics and Personalization
Artificial intelligence and machine learning can analyze patient data to predict treatment efficacy, personalize stimulation settings, and identify optimal candidates for neuromodulation therapy.
Miniaturization and Wireless Power Transfer
Advancements in battery technology and wireless charging allow for smaller, less invasive implants with extended lifespans, further enhancing patient comfort and convenience.
Impactful Policy Frameworks
FDA's New Medical Device Cybersecurity Guidance (2023)
The FDA issued final guidance in 2023 requiring medical device manufacturers to submit a cybersecurity plan for premarket submissions, emphasizing secure design and incident response.
This policy increases the burden on Axonics to ensure robust cybersecurity measures in their devices, potentially affecting development timelines and costs.
CMS Medicare Coverage for Innovative Technology (MCIT) Rule (Repealed and Re-proposed 2021/2023)
The MCIT rule aimed to provide immediate Medicare coverage for breakthrough medical devices for four years; while repealed in 2021, CMS proposed a new pathway in 2023 for faster access to innovative technologies.
While the original MCIT was repealed, future iterations or similar initiatives could accelerate Medicare coverage for Axonics' innovative SNM system, improving patient access and revenue.
U.S. Data Privacy Regulations (e.g., California Consumer Privacy Act/CPRA 2020/2023, Washington My Health My Data Act 2023)
States like California and Washington have enacted comprehensive data privacy laws, expanding consumer rights regarding personal health information and imposing strict requirements on companies collecting and processing such data.
These regulations mandate enhanced data privacy and security protocols for Axonics, especially given their patient qualification process, increasing compliance costs and data management complexity.
Transform Your Ideas into Action in Minutes with WaxWing
Sign up now and unleash the power of AI for your business growth
